Market Overview:
The global migraine headache drugs market is expected to grow at a CAGR of 5.8% during the forecast period from 2018 to 2030. The market was valued at US$ 7,711.5 Mn in 2017 and is projected to reach a value of US$ 12,362.4 Mn by 2030. The growth of the global migraine headache drugs market can be attributed to various factors such as an increase in the prevalence of migraines, rising awareness about available treatment options for migraines, and increasing research and development (R&D) activities for new migraine drugs. Based on type, the global migraine headache drugs market has been segmented into almotriptan, eletriptan, sumatriptan, rizatriptan,, zolmitriptan,, naratriptan,, frovatriptan,, and others). Sumatripatan held a dominant share in terms of revenue in 2017 owing to its high adoption rate across regions owing to its fast-acting properties compared with other triptans available in the market. Almotripatan is expected witness highest CAGR over 2018-2030 due To launch Of generic versions Of Almotripatan By Various Generic Pharmaceutical Companies In North America And Europe Region .
Product Definition:
Migraine headache drugs are medications used to prevent or treat migraines. Migraine headaches are a type of headache that is often described as throbbing or pulsing, and is usually accompanied by nausea, vomiting, and sensitivity to light or sound. Migraine headache drugs may be used to prevent migraines from occurring, or to treat them when they do occur.
Almotriptan:
Almotriptan is a selective serotonin receptor modulator (SSRM). It's mechanism of action is to constrict blood vessels which reduces the blood flow and therefore the pain. It works by binding to serotonin receptors present on sensory nerves.
It was approved in 1999 in Europe and 2000 in U.
Eletriptan:
Eletriptan is a drug that belongs to the category of medications called as vasoactive agents. It works by dilating blood vessels and increasing the flow of blood to the brain, thereby providing relief from migraine pain. Eletriptan is also used for other purposes such as treating symptoms of Raynaud's disease and cluster headache.
Application Insights:
The acute migraine segment dominated the global market in 2017. This is due to the rising prevalence of migraine and increasing awareness about treatment, especially among adults. As per WHO, migraines affect approximately 39.0 million people across the world; out of which 26.0% are men and 15.0% are women (1).
In North America, migraine affects around 3-5 million people every year (2). It is more common in females than males at a ratio of 2:1 (2) and it occurs more often during summer months as compared to winter ones (3). The most effective preventive measures against migraine include avoiding trigger factors such as food additives, alcohol consumption etc.
Regional Analysis:
North America dominated the global market in 2017. This is attributed to the presence of a large patient pool, high awareness levels coupled with easy access to medicines and better reimbursement scenario in this region as compared to other regions. The Asia Pacific is expected to witness lucrative growth over the forecast period owing to increasing prevalence of headache disorders coupled with improving healthcare infrastructure and economic development in this region. Moreover, growing number of product launches are also expected contribute towards regional growth during the forecast period. For instance, Sun Pharma’s brand name Zomig (sumatriptan) was approved for marketing by FDA in August 2015 for treating acute attacks of migraine headaches along with Zomig Migraine Treatment system which includes oral gel cap Suma-30M and nasal spray Almoten (ethambutol) Imitrex which was earlier launched under prescription only scheme by Sun Pharmaceutical Industries Ltd., India based company in 2012 after receiving approval from Indian Drug Controller General (INDCG).
Growth Factors:
- Increasing prevalence of migraine headache
- Growing awareness about the available treatments for migraine headaches
- Rising demand for effective and safe drugs to treat migraine headaches
- Availability of generic versions of branded drugs for treating migraine headaches
- Development of novel therapies and delivery systems for treating migraines
Scope Of The Report
Report Attributes
Report Details
Report Title
Migraine Headache Drugs Market Research Report
By Type
Almotriptan, Eletriptan, Sumatriptan, Rizatriptan, Zolmitriptan, Naratriptan, Frovatriptan, Others
By Application
Acute Migraine, Common Migraine, Classic Migraine, Chronic Migraine, Other Migraines
By Companies
Pfizer, Novartis, Johnson & Johnson, GSK, Merck, Eli Lilly, Teva, AstraZeneca, Sun Pharma, Grunenthal, Endo Pharmaceuticals, Mylan, Bayer, Amneal Pharmaceuticals, Apotex, Ajanta Pharma, Allergan
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
166
Number of Tables & Figures
117
Customization Available
Yes, the report can be customized as per your need.
Global Migraine Headache Drugs Market Report Segments:
The global Migraine Headache Drugs market is segmented on the basis of:
Types
Almotriptan, Eletriptan, Sumatriptan, Rizatriptan, Zolmitriptan, Naratriptan, Frovatriptan, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Acute Migraine, Common Migraine, Classic Migraine, Chronic Migraine, Other Migraines
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Novartis
- Johnson & Johnson
- GSK
- Merck
- Eli Lilly
- Teva
- AstraZeneca
- Sun Pharma
- Grunenthal
- Endo Pharmaceuticals
- Mylan
- Bayer
- Amneal Pharmaceuticals
- Apotex
- Ajanta Pharma
- Allergan
Highlights of The Migraine Headache Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Almotriptan
- Eletriptan
- Sumatriptan
- Rizatriptan
- Zolmitriptan
- Naratriptan
- Frovatriptan
- Others
- By Application:
- Acute Migraine
- Common Migraine
- Classic Migraine
- Chronic Migraine
- Other Migraines
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Migraine Headache Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Migraine headache drugs are medications that are used to relieve the symptoms of a migraine. These medications can include over-the-counter painkillers, prescription medication, and nonprescription medication.
Some of the key players operating in the migraine headache drugs market are Pfizer, Novartis, Johnson & Johnson, GSK, Merck, Eli Lilly, Teva, AstraZeneca, Sun Pharma, Grunenthal, Endo Pharmaceuticals, Mylan, Bayer, Amneal Pharmaceuticals, Apotex, Ajanta Pharma, Allergan.
The migraine headache drugs market is expected to register a CAGR of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Migraine Headache Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Migraine Headache Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Migraine Headache Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Migraine Headache Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Migraine Headache Drugs Market Size & Forecast, 2018-2028
4.5.1 Migraine Headache Drugs Market Size and Y-o-Y Growth
4.5.2 Migraine Headache Drugs Market Absolute $ Opportunity
Chapter 5 Global Migraine Headache Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Migraine Headache Drugs Market Size Forecast by Type
5.2.1 Almotriptan
5.2.2 Eletriptan
5.2.3 Sumatriptan
5.2.4 Rizatriptan
5.2.5 Zolmitriptan
5.2.6 Naratriptan
5.2.7 Frovatriptan
5.2.8 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Migraine Headache Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Migraine Headache Drugs Market Size Forecast by Applications
6.2.1 Acute Migraine
6.2.2 Common Migraine
6.2.3 Classic Migraine
6.2.4 Chronic Migraine
6.2.5 Other Migraines
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Migraine Headache Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Migraine Headache Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Migraine Headache Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Migraine Headache Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Migraine Headache Drugs Market Size Forecast by Type
9.6.1 Almotriptan
9.6.2 Eletriptan
9.6.3 Sumatriptan
9.6.4 Rizatriptan
9.6.5 Zolmitriptan
9.6.6 Naratriptan
9.6.7 Frovatriptan
9.6.8 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Migraine Headache Drugs Market Size Forecast by Applications
9.10.1 Acute Migraine
9.10.2 Common Migraine
9.10.3 Classic Migraine
9.10.4 Chronic Migraine
9.10.5 Other Migraines
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Migraine Headache Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Migraine Headache Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Migraine Headache Drugs Market Size Forecast by Type
10.6.1 Almotriptan
10.6.2 Eletriptan
10.6.3 Sumatriptan
10.6.4 Rizatriptan
10.6.5 Zolmitriptan
10.6.6 Naratriptan
10.6.7 Frovatriptan
10.6.8 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Migraine Headache Drugs Market Size Forecast by Applications
10.10.1 Acute Migraine
10.10.2 Common Migraine
10.10.3 Classic Migraine
10.10.4 Chronic Migraine
10.10.5 Other Migraines
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Migraine Headache Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Migraine Headache Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Migraine Headache Drugs Market Size Forecast by Type
11.6.1 Almotriptan
11.6.2 Eletriptan
11.6.3 Sumatriptan
11.6.4 Rizatriptan
11.6.5 Zolmitriptan
11.6.6 Naratriptan
11.6.7 Frovatriptan
11.6.8 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Migraine Headache Drugs Market Size Forecast by Applications
11.10.1 Acute Migraine
11.10.2 Common Migraine
11.10.3 Classic Migraine
11.10.4 Chronic Migraine
11.10.5 Other Migraines
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Migraine Headache Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Migraine Headache Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Migraine Headache Drugs Market Size Forecast by Type
12.6.1 Almotriptan
12.6.2 Eletriptan
12.6.3 Sumatriptan
12.6.4 Rizatriptan
12.6.5 Zolmitriptan
12.6.6 Naratriptan
12.6.7 Frovatriptan
12.6.8 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Migraine Headache Drugs Market Size Forecast by Applications
12.10.1 Acute Migraine
12.10.2 Common Migraine
12.10.3 Classic Migraine
12.10.4 Chronic Migraine
12.10.5 Other Migraines
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Migraine Headache Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Migraine Headache Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Migraine Headache Drugs Market Size Forecast by Type
13.6.1 Almotriptan
13.6.2 Eletriptan
13.6.3 Sumatriptan
13.6.4 Rizatriptan
13.6.5 Zolmitriptan
13.6.6 Naratriptan
13.6.7 Frovatriptan
13.6.8 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Migraine Headache Drugs Market Size Forecast by Applications
13.10.1 Acute Migraine
13.10.2 Common Migraine
13.10.3 Classic Migraine
13.10.4 Chronic Migraine
13.10.5 Other Migraines
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Migraine Headache Drugs Market: Competitive Dashboard
14.2 Global Migraine Headache Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 Novartis
14.3.3 Johnson & Johnson
14.3.4 GSK
14.3.5 Merck
14.3.6 Eli Lilly
14.3.7 Teva
14.3.8 AstraZeneca
14.3.9 Sun Pharma
14.3.10 Grunenthal
14.3.11 Endo Pharmaceuticals
14.3.12 Mylan
14.3.13 Bayer
14.3.14 Amneal Pharmaceuticals
14.3.15 Apotex
14.3.16 Ajanta Pharma
14.3.17 Allergan
